As expected, the "radical cure" malaria drug tafenoquine from Glaxosmithkline plc (GSK) sailed through a meeting of the FDA's Antimicrobial Drugs Advisory Committee, with panelists voting 13-0 in favor of recommending its approval based on efficacy and 12-1 for marketing clearance based on safety.